Eris Lifesciences Limited has allotted 11,233 equity shares on June 26, 2026, pursuant to the exercise of options under the ESOP-2021 Scheme. The allotment was made across three different grant years with varying exercise prices:
- 2022 Grant: 3,401 shares at an exercise price of ₹557.24 per share
- 2023 Grant: 3,662 shares at an exercise price of ₹510.32 per share
- 2024 Grant: 4,170 shares at an exercise price of ₹728.16 per share
The company's paid-up share capital has consequently increased from ₹13,85,67,256 (comprising 13,85,67,256 equity shares of ₹1 each) to ₹13,85,78,489 (comprising 13,85,78,489 equity shares of ₹1 each).
The shares were allotted under the ESOP-2021 Scheme in compliance with SEBI regulations. The newly allotted shares will rank pari-passu with the existing equity shares of the company.
Additional Announcements:
The filing does not contain any additional corporate announcements beyond the ESOP allotment disclosure.